FDA Reproductive Health Drugs Cmte. returns
Executive Summary
FDA's Reproductive Health Drugs Adivisory Committee will break a three year hiatus with a Sept. 29 meeting on clinical trial design issues and outcome measures for drugs seeking indications for induction of ovulation and pregnancy in anovulatory infertile women and development of multiple follicles in pregnancy in ovulatory women participating in assisted reproductive technology programs. It is the first meeting of the committee since Sept. 12, 2000, and since its reconstitution with new members in December 2002 (1"The Pink Sheet" Jan. 6, 2003, p. 15)...